©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Feb 15, 2024; 15(2): 133-136
Published online Feb 15, 2024. doi: 10.4239/wjd.v15.i2.133
Published online Feb 15, 2024. doi: 10.4239/wjd.v15.i2.133
Glucagon-like peptide-1 receptor agonists as a possible intervention to delay the onset of type 1 diabetes: A new horizon
Mahmoud Nassar, Ajay Chaudhuri, Husam Ghanim, Paresh Dandona, Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, NY 14221, United States
Author contributions: All authors have contributed equally to this work; All authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Mahmoud Nassar, MD, MSc, PhD, Doctor, Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, 705 Maple Road, Buffalo, NY 14221, United States. dr.nassar@aucegypt.edu
Received: November 3, 2023
Peer-review started: November 3, 2023
First decision: December 6, 2023
Revised: December 17, 2023
Accepted: January 16, 2024
Article in press: January 16, 2024
Published online: February 15, 2024
Processing time: 93 Days and 0.8 Hours
Peer-review started: November 3, 2023
First decision: December 6, 2023
Revised: December 17, 2023
Accepted: January 16, 2024
Article in press: January 16, 2024
Published online: February 15, 2024
Processing time: 93 Days and 0.8 Hours
Core Tip
Core Tip: New research suggests a novel approach to treating type 1 diabetes (T1D) by using glucagon-like peptide-1 receptor agonists, specifically semaglutide, to significantly improve blood glucose control and potentially slow the progression of the disease in newly diagnosed patients. This strategy, which leads to less insulin dependence and better metabolic markers, could change the way T1D is managed in a big way. At the same time, the study supports early T1D risk screening, especially in groups with high risk, so that early interventions can be made, evaluating the benefits against the possible emotional and financial effects. This dual approach shows that there are bright futures for improving the lives of patients with T1D.